Mar 25, 2026 | Uncategorized
J Pain. 2026 Mar 24:106269. doi: 10.1016/j.jpain.2026.106269. Online ahead of print.ABSTRACTChronic pain is common and burdensome among people with end stage kidney disease (ESKD). Pain management options are limited and prescription opioids are often used in this...
Mar 16, 2026 | Uncategorized
Subst Use Addctn J. 2026 Mar 17:29767342261421746. doi: 10.1177/29767342261421746. Online ahead of print.ABSTRACTBACKGROUND: Harm reduction services fulfill a critical need in reducing the negative consequences associated with the overdose crisis. However, many...
Mar 15, 2026 | Uncategorized
J Pain. 2026 Mar 13:106220. doi: 10.1016/j.jpain.2026.106220. Online ahead of print.ABSTRACTSingle session interventions (SSIs) for chronic pain are a novel and scalable intervention approach that are far less burdensome than typical 8-session behavioral treatments,...
Mar 15, 2026 | Uncategorized
JAMA Netw Open. 2026 Mar 2;9(3):e260667. doi: 10.1001/jamanetworkopen.2026.0667.NO ABSTRACTPMID:41838008 | DOI:10.1001/jamanetworkopen.2026.0667
Mar 11, 2026 | Uncategorized
J Addict Med. 2026 Mar 12. doi: 10.1097/ADM.0000000000001675. Online ahead of print.ABSTRACTOBJECTIVES: In 2022, the FDA issued a drug safety communication based on case studies that transmucosal buprenorphine, a medication for opioid use disorder (MOUD), may...
Mar 10, 2026 | Uncategorized
JMIR Form Res. 2026 Mar 11;10:e86070. doi: 10.2196/86070.ABSTRACTBACKGROUND: Approximately 45% of individuals taking methadone or buprenorphine have chronic pain. These medications are commonly prescribed for chronic pain or opioid use disorder (OUD). To optimize pain...
